USDA Licensed Test Kits and Enhanced Surveillance for BSE Larry Ludemann 1 and Lawrence Elsken 2 Policy, Evaluation, and Licensing 1 Inspection and Compliance.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Unit 6 Diagnosis & Follow-up of HIV Infection
Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.
Comparison of the HIV LIA vs WB on HIV-Negative Samples CDC-HIV Diagnostics Meeting “New Diagnostic Technologies” Dec 5-7, 2007 Dr. John Kim National Laboratory.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Teaching Workshop Bovine Spongiform Encephalopathy (BSE) Air-injection Stunning.
Food Safety and Inspection Service Overview of New Regulations and Policies to Further Enhance Safeguards Against Bovine Spongiform Encephalopathy (BSE)
1 Lecture: Forensic Serology - Immunoassays Antibody/Antigen reaction provides the means of generating a measurable result. “Immuno” refers to an immune.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Experimental pathology refers to the observation of the effects of manipulations on animal models or cell cultures regarding researches on human diseases.
Immunohistochemistry
Bovine Spongiform Encephalopathy Luke VanNatter Carrie Pell Amy Richwine Scott Inskeep Kristina Anderson.
Special Topics in IND Regulation
Enzyme-linked Immunosorbent Assay
Complement based techniques Complex protein system by which certain antibodies are capable of killing cells Proteins of the complex system are thermolabile.
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download,
CBER's policies on assay regulation: Definitions of assay performance characteristics Andrew I. Dayton, M.D., Ph.D. CBER.
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
HIV Testing CDC power point edited by M. Myers
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
HIV Testing Quality Assurance and Quality Control
(Enzyme Linked Immunosorbent Assay)
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.
The Nature of Disease.
HIV/AIDS is preventable and treatable, but is incurable.
Teaching Workshop Bovine Spongiform Encephalopathy (BSE)
MEDICAL TESTING Doctor requires information Patient sample collection
Western Blotting.
Laboratory diagnosis of infectious and non infectious diseases The methods employed in the laboratory for diagnosing infectious (bacterial, viral, fungal,
BSE in the US APHIS Investigation and Response FDA TSE Advisory Committee February 12, 2004 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS,
Enzyme-Linked Immunosorbent Assay [ELISA] BCH 462[practical] Lab#5.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Quarantine and Movement Control Overview Adapted from the FAD PReP/NAHEMS Guidelines: Quarantine and Movement Control (2014)
Dr K N Prasad Community Medicine
1 Immunoassay Testing Forensic Toxicology. 2 Introduction Antibody/Antigen reaction provides the means of generating a measurable result. “Immuno” refers.
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
BSE: World Situation and USDA Response FDA TSE Advisory Committee Silver Spring, MD October 14, 2004 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA,
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
Overview of FDA's Regulatory Framework for PET Drugs
IMMUNOLOGY. IMMUNITY Immunity is the resistance of a host to invasive pathogens or their toxic products.
John Gray, Sandor Dudas and Stefanie Czub
HIV/AIDS is preventable and treatable, but is incurable.
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.
Surveillance, Epidemiology, and Tracing Surveillance Part 2: Implementing Surveillance Adapted from the FAD PReP/NAHEMS Guidelines: Surveillance, Epidemiology,
10 May Understanding diagnostic tests Evan Sergeant AusVet Animal Health Services.
BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
United States Department of Agriculture Food Safety and Inspection Service Overview of Trim Sampling Compliance Guidelines and Discussion Daniel Engeljohn,
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
BioPlex 2200 HIV Ag-Ab Assay
Regulatory Perspective on Trends in Veterinary Biologics Byron Rippke, DVM Nancy Clough, DVM, PhD Director, Center for Veterinary Biologics U.S. Department.
Freeda E. Isaac, DVM Director: Organisms, Vectors and Select Agents National Center of Import Export Veterinary Services November 14, 2012.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
ICC Immunocytochemistry
Introduction to Quality Assurance. Quality assurance vs. Quality control.
Specimen Collection Guide for Cattle or Horses with Suspected Rabies, West Nile Virus Encephalitis or Bovine Spongiform Encephalopathy (BSE) Adapted from.
QUALITATIVE RISK ASSESSMET
Diagnosing Infections
Introduction To Medical Technology
Presentation transcript:

USDA Licensed Test Kits and Enhanced Surveillance for BSE Larry Ludemann 1 and Lawrence Elsken 2 Policy, Evaluation, and Licensing 1 Inspection and Compliance 2 Center for Veterinary Biologics Veterinary Services Animal and Plant Health Inspection Service United States Department of Agriculture 510 S. 17 th Street, Suite 104 Ames, Iowa USA

The Causative Agent of TSEs  Prions Abnormally folded proteinAbnormally folded protein  Not a virus. Not a bacteria. No DNA or RNA  No known immune response Two forms of prion proteinTwo forms of prion protein  Normal prion protein (PrPc) – on most cells  Infectious Prion (PrPSc) Relatively resistant to disinfectants, sterilizations, proteinasesRelatively resistant to disinfectants, sterilizations, proteinases Accumulates and kills the cellsAccumulates and kills the cells

BSE: Diagnostics  No effective live animal test for BSE  Need brain tissue  Histopathology of brain  IHC, WB, ELISA – PrP res  “Negatives” do not guarantee absence of infectivity - tests are NOT intended as “Food Safety Tests”

BSE Diagnostic Tests   Histology  ImmunoHistochemistry (IHC)-  ImmunoHistochemistry (IHC)-an ELISA performed on a tissue section mounted on a slide   “Rapid tests”- ELISA, EIA, Western Blot

“Rapid Tests”  As name implies, generally more rapid than IHC  Associated with occasional “false positive” initial reactions (especially ELISA)  Western Blot Test lower throughput, slower, and more involved than ELISA  All approved tests have very good sensitivity and specificity  BUT - only serve as screening tests

IMMUNOHISTOCHEMISTRY  Adds immunological confirmation to observation of lesions  Stain observed in specific (definitive) anatomic areas associated with BSE  No “false positives”  Generally requires several days to complete test

January 8, 2004 CENTER FOR VETERINARY BIOLOGICS NOTICE NO Subject: Diagnostic Test Kits for Bovine Spongiform Encephalopathy To: Biologics Licensees, Permittees, and Applicants Veterinary Services Management Team Directors, Center for Veterinary Biologics Area Veterinarians in Charge, VS State Veterinarians I. PURPOSE The purpose of this notice is to inform interested parties that the Center for Veterinary Biologics (CVB) is accepting veterinary biologics product license and permit applications for diagnostic test kits (including “rapid tests”) intended as an aid in the diagnosis of bovine spongiform encephalopathy (BSE). II. Background Numerous test methods (e.g., immunohistochemistry, ELISA, Western blot) and commercial test kits have been developed to aid in the diagnosis of BSE. Some of these kits have been approved by foreign regulatory officials (e.g., European Union, Japan) for use in their BSE testing programs. Due to recent confirmed cases of BSE in North America and the anticipated increase in surveillance for BSE in the U.S., the CVB will accept and consider license and permit applications for diagnostic test kits intended to aid in the diagnosis of BSE. The CVB will proceed with the review and testing processes of each license or permit application up to the point of issuing the actual U.S. Veterinary Biological Product License or Permit. In the future, the CVB will issue additional guidance on the final U.S. Veterinary Biological Product License or Permit restrictions required for distribution and sale of these diagnostic test kits in the U.S.

Authorities, Regulations, & Guidance  Virus-Serum-Toxin Act: 21 USC Authorizes Secretary of Agriculture to regulate manufacture and distribution of biologics including diagnostics (test kits) intended for use in diagnosis of disease in animals.Authorizes Secretary of Agriculture to regulate manufacture and distribution of biologics including diagnostics (test kits) intended for use in diagnosis of disease in animals.  Code of Federal Regulations: Title 9  VS Memoranda (Immunodiagnostic Test Kits), others (Immunodiagnostic Test Kits), others

What is a regulated test kit?  Diagnostic test kits contain: All unique reagents required to conduct testAll unique reagents required to conduct test Complete instructions for the testComplete instructions for the test Instructions for interpretation of test resultsInstructions for interpretation of test results Claims, uses, and limitationsClaims, uses, and limitations  Used to diagnose existence of (usually) or susceptibility to disease agents of animals  Reagents are not regulated

Prelicense Assessment of Kits  Accuracy and precision  Diagnostic sensitivity Dynamic rangeDynamic range Analytical sensitivityAnalytical sensitivity  Diagnostic specificity  Ruggedness, repeatability, suitability  Predictive values for specific disease prevalence (especially for Program Diseases)

Prelicense Validation  Test large number of known positive and known negative animal samples covering a range of reactions and all sample types  Determine onset of detection of disease  Evaluate (in at least 3 laboratory settings) Serum or antigen panel (ruggedness)Serum or antigen panel (ruggedness) Well-characterized patient samplesWell-characterized patient samples Compared to “Gold” standard assayCompared to “Gold” standard assay Suitability of test kitSuitability of test kit Adequacy of instructionsAdequacy of instructions  Authorization from USDA per 9 CFR (experimental biological products)

Manufacturing controls  Aim is to minimize within-serial and serial- to-serial variation by ensuring consistency of production – Outline of Production  Master Seed/Master Cell concept  Validation of new lots of antibody/antisera  Serial release testing of serum or antigen panel with range of reactivities and cross- reactivities Serial release panel is critical to minimize variation in test resultsSerial release panel is critical to minimize variation in test results Panel includes range of reactivityPanel includes range of reactivity

Other Requirements  Inspection of manufacturing facilities and other licensed sites (e.g., Permittee quarantine sites)  Prelicense serial testing  Label approval

USDA Approved Bovine Spongiform Encephalopathy Antigen Test Kits (Permits, as of September 30, 2004) Manufacturer Kit Format Trade Name Date Approved Bio-Rad Laboratories, (permittee: Bio-Rad, France) ELISATeSeE® Permit issued: March 17, 2004 Abbott Laboratories (permittee: Enfer, Ireland) ELISA Enfer BSE Permit issued: May 28, 2004 Roche Diagnostics Corp., (permittee Prionics, (permittee Prionics, Switzerland) Switzerland) Western Blot Prionics®- Check Western Permit issued: May 28, 2004

USDA Approved Bovine Spongiform Encephalopathy Antigen Test Kits Licenses, as of (September 30, 2004) Manufacturer Kit Format Trade Name Date Approved IDEXX Laboratories, Inc. EIA (Enzyme Immunoassa y) HerdChek- BSE License issued: March 17, 2004 Pierce Biotechnology, Inc., (Produces kit for Prionics) ELISA Prionics®- Check LIA Licensed: September 1, 2004 Pierce Biotechnology, Inc., For Export Only ELISABSE-Scrapie Ag Test Kit Prionics®- Check LIA Licensed: September 1, 2004 VMRD, Inc. For Export Only IHC License issued: August 5, 2004

Licensed BSE Test Kits: Format or Technique  All use obex tissue  Purify normal and abnormal PrP  Treatment to “remove” normal PrP Western Blot – separate protein by Mol WtWestern Blot – separate protein by Mol Wt  Antibody binds “abnormal” PrP  Indicator enzyme (on antibody) produces “visible” reaction: ELISA, EIA, chemiluminescence, solid precipitate (Western Blot, IHC)ELISA, EIA, chemiluminescence, solid precipitate (Western Blot, IHC)

Diagnostics: Under Development  “Cowside” or on-site tests  Capillary electrophoresis – blood  Blood – other methodologies - Capture  Urine – UPrPsc  Increased sensitivity – cyclic amplification  Non-PrP markers – “Upregulated” Markers

What does licensure provide?  USDA controlled manufacturing of all components and kits Minimal variation within and between serialsMinimal variation within and between serials  USDA evaluation of test kit before and after licensure (serial release)  Monitoring of field performance and investigations CVB-Inspection and Compliance CVB-Inspection and Compliance  Ongoing facilities inspections  Questions?

BSE Surveillance Program  Expanded or Enhanced surveillance began June 1, Purpose: Determine if BSE is present in U.S. cattle populationDetermine if BSE is present in U.S. cattle population Determine if risk-management policies adequateDetermine if risk-management policies adequate  For animal health – NOT food safety

EU testing: Jan-Dec 2001 SamplesPositive% positive Risk 776, % Em slaug 96, % CNS 27, % Fallen 651, % Healthy7,677, % Suspect 3, %

BSE Surveillance Program   Experience in Europe has demonstrated that targeting surveillance efforts at certain high risk populations is the most effective way to identify BSE, if it is present.

BSE Surveillance Program  US high-risk population estimate: about 446, ,000 on-farm deaths with unexplained causes or causes consistent with BSE246,000 on-farm deaths with unexplained causes or causes consistent with BSE 200,000 ante-mortem condemnations by FSIS200,000 ante-mortem condemnations by FSIS 129 (2004 data) Foreign Animal Disease investigations for CNS disease129 (2004 data) Foreign Animal Disease investigations for CNS disease

BSE Surveillance Program  The majority of samples from the following categories: Nonambulatory cattle;Nonambulatory cattle; Cattle exhibiting signs of a central nervous system disorder;Cattle exhibiting signs of a central nervous system disorder; Cattle exhibiting other signs that may be associated with BSE, such as emaciation or injury; andCattle exhibiting other signs that may be associated with BSE, such as emaciation or injury; and Dead cattle.Dead cattle.  USDA personnel will also sample all cattle condemned on ante-mortem inspection by USDA’s Food Safety and Inspection Service.)

BSE Surveillance Program   If 268,500 samples are obtained from a target population of 446,000, and if no positives were found after completion of the testing plan, then we can state that we are 99 percent confident that there were less than 5 positive animals in the target population

BSE Surveillance Program  Enhanced surveillance plan background, statistical inferences: issues/bse/bse.htmlhttp://cofcs66.aphis.usda.gov/lpa/ issues/bse/bse.html

BSE Surveillance Program  As of October 10, 2004, no positive BSE test results in Enhanced Surveillance Program Cumulative “rapid” tests from June 1, 2004 – October 10, 2004: 79,766Cumulative “rapid” tests from June 1, 2004 – October 10, 2004: 79,766 Also 1,583 IHN negative testsAlso 1,583 IHN negative tests Currently: More than 5,000/weekCurrently: More than 5,000/week se_testing/test_results.htmlhttp:// se_testing/test_results.html